by Heather R. Romeroa, Andreas U. Monsch, Kathleen M. Hayden, Brenda L. Plassman, Alexandra S. Atkins, Richard S. E. Keefe, Shyama Brewster, Carl Chiang, Janet O’Neil, Grant Runyan, Mark J. Atkinson, Stephen Crawford, Kumar Budur, Daniel K. Burns, Kathleen A. Welsh-Bohmer

 

Introduction: Assessment of preclinical Alzheimer’s disease (AD) requires reliable and validated methods to detect subtle cognitive changes. The battery of standardized cognitive assessments that is used for diagnostic criteria for mild cognitive impairment due to AD in the TOMMORROW study have only been fully validated in English-speaking countries. We conducted a validation and norma-tive study of the German language version of the TOMMORROW neuropsychological test battery, which tests episodic memory, language, visuospatial ability, executive function, and attention…